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Introduction 
There is a public misconception that persons with mental disorders are 
'bad' rather than 'ill' in the medical sense of the word. This fosters the 
apprehension that the mentally ill are dangerous, that they should be 
locked up and kept away from society. However the advent of 
psychotropic medications has allowed many persons with psychiatric 
disorders to spend less time in mental hospitals and more time in the 
community (Costas, 1990). Among the mental hospital diseases that 
have been misconceived is schizophrenia. 
In the twentieth century there was the introduction of medical treatment 
for schizophrenia, but it was only after the success achieved by 
chloropromazine in 1952 that other new drugs, some with similar 
structures while others with different structures, were introduced. 
Action of neuroleptics can be divided into two classes: wanted and 
unwanted effects (Rosenthal et aI, 1975). 
1. Wanted effects: sedative effect; 
antidelusional effects; and 
disinhibitory effects. 
2. Unwanted effects: sleepiness; 
early hyperkinesia and anxiety or 
suggestibility; 
parkinsonian syndrome (akinesia, hypertonia, 
tremor) and depressive tendencies, and later 
occurrence of hyperkinetic syndrome 
(akathesia, restlessness) and insomnia or 
neuroticism. 
'Social measures are also important therapeutically. These along with 
other drugs have a protective effect both in schizophrenics who return 
with their families and also in those patients who are living alone and 
therefore exposed to stressful life events. 
Aims 
In Malta, Mount Ca.nnel Hospital, is the principal mental hospital. 
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The following studies were carried out considering schizophrenia and its 
treatment having the following aims: 
Study 1 - To determine the combination therapies prescribed in Malta to 
schizophrenic outpatients during 1991 according to sex and age group. 
Study 2 - To study use of anti psycho tics in all diseases that have been 
diagnosed at Mount Carmel Hospital between 1987 and 1991 according to 
sex and age group. 
This study has been further subdivided into three further studies with 
the following aims:-
Study 2.1 - To establish the prevalence of diseases diagnosed at Mount 
Carmel Hospital between 1987 and 1991. 
Study 2.2 - To establish the sex and age group in which schizophrenia 
has been most commonly diagnosed at Mount Carmel Hospital between 
1987 and 1991. 
Study 2.3 - To establish the extent of the use of antipsychotics in 
schizophrenia at Mount Carmel Hospital between 1987 and 1991. 
Study 3 - To study the prognosis of schizophrenia in Maltese patients. 
Study 4 - To correlate the relapse rate of schizophrenia in Malta 
according to sex. 
Study 5 - A study of the Maltese schizophrenic patients in the 
community. This study was further subdivided into five further studies 
with the following aims:-
Study 5.1 - Social details of Maltese schizophrenic patients living in the 
community. 
Study 5.2 - The knowledge that the schizophrenic patients and family 
members / carers have concerning the disease itself and its treatment. 
Study 5.3 - Patient compliance to prescribed treatment. 
Study 5.4 - The practice of ECT in Malta. 
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Study 5.5 - The confidence of Maltese schizophrenic patients and family 
members / carers in their community pharmacist. 
Study 6 - The role of the pharmacist regarding the special needs of 
patients with mental disorders. 
This last study was subdivided into five further studies with the 
following aims :-
Study 6.1 - The adequacy of the curricular content of the undergraduate 
B.Pharm (Hons) course on psychotropic medications and the needs of 
patients on such treatment. 
Study 6.2 - The most common psychotropic drugs being prescribed in the 
community. 
Study 6.3 - Number of patients on psychotropic medication in the 
community. 
Study 6.4 - How the pharmacist ensures patient compliance. 
Study 6.5 - Response of pharmacists to proposed home visits. 
Methodology 
Study! 
Therapy as recorded on the treatment yellow cards of schizophrenic 
outpatients during 1991 was used. 
For the purpose of this study all drugs were grouped into five classes: 
a) Antipsychotics (AP) - including those drugs used in psychosis and 
rela ted disorders, that is antipsychotic drugs, for example, 
phenothiazines and depot injections, for example, thioxanthenes 
and antimanic drugs, for example, lithium. 
b) Antidepressants (AD) - including tricyclic and related 
antidepressants, the mono-amine oxidase inhibitors, the combined 
antidepressant preparations and any other antidepressant drugs; 
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c) Antimuscarinics (AM) - including those drugs used in parkinsonism 
and other related disorders, for example benzhexol hydrochloride, 
orphenadrine hydrochloride and benztropine mesylate among 
others; 
d) Sedatives (S) - including hypnotics, anxiolytics, barbiturates and 
methyprylone; and 
e) Others (0) - incorporating any other drug(s) taken by the patient 
which does not fall in anyone of the above mentioned classes. 
Ages of patients were sub-divided into seven groups: 
a) 0-14 years - Age group I; 
b) 15-24 years - Age group 11; 
c) 25-34 years - Age group Ill; 
d) 35-44 years - Age group IV; 
e) 45-54 years - Age group V; 
f) 55-64 years - Age group VI; and 
g) >65 years - Age group VII 
A table was set up for each age group and combination therapies 
according to sex were recorded. 
Study 2 
Medication as recorded on treatment cards of all patients hospitalised at 
Mount Carrnel between 1987 and 1991 was recorded. 
Drugs and ages were subdivided as in Study 1, while diseases were 
grouped into the following nine classes: 
a) anxiety; 
b) depression; 
c) obsessive compulsive neurosis; 
d) organic psychosis; 
e) schizophrenia; 
f) manic depressive psychosis; 
g) personality disorder; 
h) mental handicap; and 
i) other 
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Study 3 
Modes of discharge from Mount Carmel Hospital for schizophrenic 
patients were noted from the patients' histories and were grouped under 
six headings: 
a) not requiring hospital treatment; 
b) relieved on request; 
c) not improved, relieved against medical advice; 
d) transferred; 
e) recovered; 
f) died 
Study 4 
Admissions as recorded in histories of schizophrenic patients being 
admitted to Mount Carmel Hospital between 1987 and 1991 were used. 
Study 5 
For the purpose of this study a questionnaire was set up, whereby 50 
schizophrenic patients who attended the Outpatient's Unit at St Luke's 
Hospital were interviewed. 
The questionnaire was subdivided into four main studies: 
a) biodata; 
b) social details; 
c) disease; and 
d) medication 
Study 6 
A questionnaire was sent to 100 community pharmacists in the various 
towns and village,s in Malta. 
This questionnaire was subdivided into four sections: 
a) biodata; 
b) knowledge of pharmacists about psychotropic; 
c) choice of psychotropic medication; and 
d) pharmacist-patient relationship 
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Results and Discussion 
Prevalence of schizophrenia 
In Malta schizophrenia is one of the most commonly diagnosed mental 
disorder at Mount Carmel Hospital. Indeed between 1987 and 1991, 88 
(43.35%) patients out of 203, 114 (41.30%) patients out of276, 100 (37.18%) 
patients out of 269, 120 (34.48%) patients out of 348, and 152 (33.85%) 
patients out of 449 were diagnosed, for each year respectively. 
According to this study, it appears that schizophrenia is more common in 
females than in males since over the five year period studies there were 
more females (302) than males (272) diagnosed with the disease, out of a 
total of 574 patients. 
Age group 
On comparing age groups of outpatients and inpatients, age group IV 
(35-44),.included the largest number of patients in both cases. 'This does 
not however mean that the onset of the disease lies in this age group. 
Therapy 
Most patients were given antipsychotics as part of their treatment, 
however medication in the schizophrenic inpatients was being 
continually changed till the patients were stabilised. 
In order to be able to establis):l which combination therapy is most 
commonly prescribed to Maltese schizophrenics, therapy from treatment 
cards of the outpatients sector was studied, because such patients are 
effectively stabilised and have returned to the community on 
maintenance therapy. 
The age groups 11 to VI, that is between 15-64 years' of age were 
considered. The following trend was observed among 1992 patients out of 
2332 patients: 
a. Females - AD + 5 with 40 patients; 
AP + AD + 5 with 132 patients; and 
AP + AD + AM with 41 patients 
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b. Males AD + S with 19 patients; 
AP + AM with 42 patients; 
AP + AD + S with 32 patients; and 
AP + AD + AM with 39 patients 
Patients diagnosed with schizophrenia will never recover, therapy 
needs to be maintained throughout their life. When modes of discharge 
were studied it was found that no patients recovered. The most common 
mode of discharge was:- not requiring hospital treatment with 298 
patients. Therapy still had to be taken by these patients once 
discharged and they were all given appointments to be re-assessed by 
their psychiatrist at the Outpatient's Unit at St Luke's Hospital. 
In females the most common combination therapy was AP + AD + S. Age 
groups of schizophrenic female patients on such a therapy were:- age 
group III (25-34 years) with 31 patients, age group IV (35-44 years) with 
59 patients, and age group VI (55-64 years) with 42 patien~s. 
In males, the most common combination therapy was AP + AM, with 19 
patients in age group II (15-24 years) and 23 patients in age group V (45-54 
years). 
As is expected, antipsychotics are the drugs of choice in the treatment of 
schizophrenia. Very often patients are prescribed more than one type of 
antipsychotic, however because of the large sample size involved in this 
study, the most prevalent antipsychotic and formulation prescribed could 
not be studied. 
Side effects (Chart 1) and lack of symptoms motivate patients to stop the 
medication on their own initiative and as a consequence relapse occurs. In 
fact re-admission rate over the five year period studied increased for 
both the female and male sexes. 
This is where the role of the pharmacist in responding to the special 
needs of mental patients becomes significant. It is not enough that 
patients and family members/carers are informed about the patient's 
medication. The patient now will be living in the community and thus 
could find help very easily from a community pharmacist without 
having to go to hospital to seek advice. 
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Patient compliance 
Only 1 (2%) patient from 50 was aware of his mental condition and knew 
why he was taking the medication prescribed. There were 2 (4%) 
patients who were not compliant, while the remaining 47 (94%) were 
compliant. Out of these latter 47 patients, 37 (78.72%) were compliant 
because of an experienced relapse while the remaining 10 (21.28%) 
patients simply obeyed the doctor's orders. 
This reinforces the fact that the community pharmacist should be kept 
informed. That patients do not know the name of the condition from 
which they are suffering is expected, however family members/ carers 
would be aware of the patient's mental state and the community 
pharmacist, who is easily reached, could be of beneficial help to both 
the patients and their family members/ carers. 
It seems however, that both patients and family members/carers are 
unaware of this opportunity since out of the 50 interviewed patients, only 
11 (22%) have informed their community pharmacist about the 
medication that they are taking (Chart 2). Both the psychiatrist and 
the hospital pharmacist should encourage patients and their family 
members/ carers to confide with a nearby community pharmacist. 
Community pharmacist 
Out of the 100 questionnaires sent to community pharmacists in the 
various towns and villages of Malta, 41 responded. 
The MaJtese com,munity pharmacist is very much aware of the special 
needs that mental patients require. On enquiring about their 
undergraduate curriculum, most (98%) feel that it is sufficient, however 
,all pharmacists have agreed that further information/education would 
be in order. 
Pharmacy schools and continuing education providers should place 
increased emphasis on the counselling and monitoring of patients with 
special needs, such as those with mental illness, to better prepare all 
pharmacists for the real-life demands of their profession (Myers, 1989). 
One way in which ~his could be done is by organising ward rounds at 
Mount Carmel Hospital accompanied by a pharmacist and a 
psychiatrist. 
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COMMUNITY PHARMACIST 
POSITIVE RESPONSE 22% 
1 1 
NEGATIVE RESPONSE 78% 
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A most significant international recognition of the role of pharmacists in 
the use and misuse of psychoactive substances was entrenched in a United 
Nations Resolution (The Pharmacist, 1988). 
Community pharmacists are very much aware of the need for patients 
with mental disorders to comply and to take their medication properly. 
The majority of those pharmacists who have responded the part of the 
questionnaire concerning home visits, have all agreed that such an act 
should be encouraged - 56.1 % (Chart 3). 
Other suggestions given by the community pharmacists themselves 
concerning the special needs of such patients have been: 
a) vigilance for side effects; 
b) listening to patients and devoting more time and attention to them; 
c) keeping patient medication records, preferably computerised; 
d) giving patients more information about their medication; 
e) assuring patient that pharmacist is always available and ready to 
help; 
f) keeping in touch with both their general practitioner and 
psychiatrist; and 
g) ensuring that patient is taking doses prescribed by psychiatrist. 
These are summarised in chart 4. 
General Discussion 
Schizophrenia is the most prevalent mental disorder diagnosed in Malta 
in the period 1987 to 1991. The most commonly used therapies include a 
combination of antipsychiatrics, antidepressants and sedatives in 132 
females ages ranging from 25 to 44 years and between 55 to 64 years; and 
antipsychotics and antimuscarinics in 42 male patients ages ranging from 
15 to 44 years and from 45 to 54 years. 
Neuroleptics are not a cure, and life-long treatment is required (Myers, 
1989). Because of the development of side effects, patients may often 
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MALE AND FEMALE COMMUNITY PHARMACISTS 
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56.10% 
NO RESPONSE 7 
17.07% 
NEGATIVE RESPONSE 11 
26.83% 
resort to visiting a nearby pharmacist to ask for further information. 
Indeed community pharmacists are in a position to make an important 
contribution to patient care and public knowledge (Mottram, 1989). 
Psychiatric patients may never have an adequate grasp of their illness. 
Lack in understanding why they have to take medication or why they 
have to keep taking it when they are no longer symptomatic; lack in 
understanding the instructions given; and proneness to forgetting the 
daily required dosage, are all faCtors that have an impact on patient 
compliance (Blackwell, 1973). 
To compound the matter, outpatient schizophrenic patients have a great 
unmet need for explanations about the nature of their condition, its causes 
and therapeutic measures undertaken (Pullar, 1990). Furthermore because 
of the social schizophrenic patients are entitled to obtain their 
medication free either from the hospital pharmacy or from a district 
health centre, this may contribute to lack in confidentiality between 
patients and community pharmacists. 
This brings challenges to the community pharmacists. Pharmacists are 
professionals and are bound by his or her ethical code to maintain 
confidentiality. Both doctors and hospital pharmacists should encourage 
patients to confide with a community pharmacist. 
Conclusion 
Intercommunication between the hospital pharmacist, doctor and 
psychiatrist, community pharmacist and patient with family 
members/ carers, creates a liaison between all involved and all having a 
common concern: the health of the schizophrenic patient (Figure 1). 
With the health of the population in mind, the Government votes large 
sums of money in order to achieve its projects. One suggestion that may be 
offered here is that the community pharmacist will be entrusted with 
the welfare of a manageable number of schizophrenic patients, so that 
the benefits of the above mentioned liaison may be effected. 
Amongst other duties the community pharmacist will dispense 
medications required under a national health service scheme, visits the 
patients at home, check on regular intake and administration of 
medicaments received, check also on any arising side effects and have a 
frank talk with the people around the patient. The community 
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pharmacist will appear to have become a member of the house, an aim 
that can only be secured by regular visits . 
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